KHIDI USA President: “Expanding Support for K-Bio Beyond Boston to the Entire United States”
- KHIDI USA
- Jul 7
- 3 min read
Advanced Bio Innovation Hub to Serve as a Comprehensive Platform Connecting Industry, Academia, Research, and Healthcare
By Sang-woo Roh | San Diego (2026-06-28 09:00, etoday)
The Korea Health Industry Development Institute (KHIDI) is expanding its support system for Korean biotech companies beyond Boston to encompass the entire United States. Building upon its successful Boston model, KHIDI aims to evolve into a comprehensive platform that supports every stage of global market entry—from local establishment and business development to clinical validation, investment, and strategic partnerships among industry, academia, research institutions, and healthcare providers.
In an interview with The Korea Economic Daily during the BIO International Convention 2026 in San Diego on June 25 (local time), Hyunchul Kim, President of KHIDI USA, emphasized the institute’s evolving mission.
“While our primary focus has been supporting Korean biotech and medical device companies entering the U.S. through Boston, we are now expanding our role to facilitate meaningful collaborations and strategic connections across the entire United States.”
Since opening its U.S. office in Boston in 2021, KHIDI has concentrated on helping Korean companies establish a presence in the U.S. market. Located within the Cambridge Innovation Center (CIC), KHIDI currently supports 45 Korean biotech companies through the C&D Incubation Center, providing assistance with market entry, business development, regulatory guidance, and connections to local experts and innovation networks.
“Initially, our role was to serve as a gateway to the U.S. market,” Kim explained. “Today, we are placing greater emphasis on programs that deliver tangible outcomes, including webinars, venture capital networking, business development support, and clinical validation partnerships with leading hospitals and healthcare institutions.”
Expanding Beyond Boston
KHIDI’s activities are increasingly extending beyond Boston to other major U.S. life science hubs, including New Jersey and Houston.
“We are broadening our geographic reach beyond Boston to regions where Korean companies have growing opportunities,” Kim said. “New Jersey, in particular, is strategically important because of its proximity to New York and its concentration of multinational pharmaceutical companies.”
Earlier this month, SK Biopharmaceuticals launched SK Life Science LinX, an open innovation space at its U.S. subsidiary in New Jersey to support the global expansion of Korean pharmaceutical and biotech companies. The initiative was established in collaboration with KHIDI, KOTRA, Hallym University, and the Korean American Society in Biotech and Pharmaceuticals (KASBP).
According to Kim, the project reflects the Korean government’s broader strategy of providing coordinated support through a unified public-private ecosystem.
“Rather than having each organization operate independently, the goal is to work as one team to support Korean biotech companies. SK Biopharmaceuticals’ available incubation space and KHIDI’s experience supporting companies in Boston created an ideal opportunity for collaboration.”
Launch of the Advanced Bio Innovation Hub
KHIDI USA is also preparing to launch the Advanced Bio Innovation Hub during the second half of this year.
The new hub will expand KHIDI’s mission beyond supporting individual companies to creating a collaborative ecosystem that connects industry, academia, research institutions, and hospitals. The initiative is designed to accelerate innovation by facilitating research collaboration, technology commercialization, and global partnerships.
“Even outstanding technologies often fail to reach commercialization because researchers cannot identify the right partners in the United States,” Kim noted. “Korean researchers and companies also face challenges navigating intellectual property, legal agreements, and indirect cost issues when collaborating with U.S. universities. Through the Advanced Bio Innovation Hub, we aim to provide end-to-end support so that innovative technologies can successfully progress from research to commercialization and ultimately reach patients.”
New Opportunities for K-Bio
Kim believes that recent shifts in the global biopharmaceutical landscape are creating new opportunities for Korean companies.
“As regulatory scrutiny and geopolitical concerns surrounding Chinese biotech companies continue to increase, multinational pharmaceutical companies are actively diversifying their innovation portfolios. This has significantly increased global interest in Korean biotech compared to previous years.”
However, he emphasized that stronger Business Development (BD) capabilities will be essential for Korean companies to capitalize on these opportunities.
“Business Development is far more than sales. It requires a comprehensive understanding of basic research, clinical development, partnering, negotiations, and investment. Although Korean companies possess excellent technologies, many still lack professionals with extensive global BD experience. Without the ability to articulate scientific and commercial value in a way that resonates with global pharmaceutical companies, promising innovations may not receive the recognition they deserve. Building opportunities for companies to gain experience and receive mentorship within the U.S. innovation ecosystem is therefore critical.”
Kim concluded by emphasizing that Korea’s strong innovation pipeline alone will not guarantee global success.
“Korea is often recognized as having one of the world’s largest biotech pipelines. However, we must now evaluate objectively whether these pipelines possess true global competitiveness. Sustainable success for K-Bio will require strategic focus, stronger business development capabilities, and a sophisticated strategy tailored to the U.S. market.”
